{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-254708","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-06-03T13:04:18+00:00","discovered_at":"2026-06-03T13:05:01.468965+00:00","generated_at":"2026-06-03T13:05:11.703646+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome settles all SUNOSI patent litigation; generic entry deferred to 2040","bullets":["Resolved all outstanding SUNOSI patent litigation with the last first-to-file generic applicant.","Settlement grants five companies right to sell generic SUNOSI starting September 1, 2040 (if pediatric exclusivity) or March 1, 2040.","No other patent litigation remains for SUNOSI.","Settlement will be submitted to FTC and DOJ for review as required by law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-254708","json":"https://secwatch.observer/filing/0001193125-26-254708.json","markdown":"https://secwatch.observer/filing/0001193125-26-254708.md","text":"https://secwatch.observer/filing/0001193125-26-254708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526254708/0001193125-26-254708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526254708/axsm-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:05:11.703646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}